Ticagrelor Improves Endothelial Function by Decreasing Circulating Epidermal Growth Factor (EGF)

Ticagrelor is one of the most powerful P2Y(12) inhibitor. We have recently reported that, in patients with concomitant Stable Coronary Artery Disease (SCAD) and Chronic Obstructive Pulmonary Disease (COPD) undergoing percutaneous coronary intervention (PCI), treatment with ticagrelor, as compared to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Physiol
Autors principals: Vieceli Dalla Sega, Francesco, Fortini, Francesca, Aquila, Giorgio, Pavasini, Rita, Biscaglia, Simone, Bernucci, Davide, Del Franco, Annamaria, Tonet, Elisabetta, Rizzo, Paola, Ferrari, Roberto, Campo, Gianluca
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2018
Matèries:
Physiology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5900783/
https://ncbi.nlm.nih.gov/pubmed/29686623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphys.2018.00337
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars